Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/13/2025

Management of Chemotherapy-Induced Neuropathy

Introduction to Chemotherapy-Induced Neuropathy

  • Chemotherapy-induced neuropathy is a type of chronic neuropathic pain, as defined by the American Society of Clinical Oncology, with cancer-related pain (chemotherapy-induced neuropathy) 1
  • Symptoms of chemotherapy-induced neuropathy can be poorly controlled by maximum medical therapy, including failed trials of first-line medications (Gabapentin and Cymbalta), according to the American Society of Clinical Oncology 1
  • Patients with CRPS who have failed conservative treatment for 3+ months meet the Aetna CPB criteria, as stated by the Aetna Clinical Policy Bulletin 1

Pharmacological Options

  • Duloxetine (Cymbalta) is a first-line treatment for chemotherapy-induced peripheral neuropathy (CIPN) with Level I, B evidence, as recommended by the American Society of Clinical Oncology 1
  • Gabapentin/Pregabalin are second-line treatments for neuropathic pain, according to the American Academy of Neurology 1 and the American Society of Clinical Oncology 2

Interventional Procedures

  • Lumbar sympathetic nerve block can provide both diagnostic and therapeutic benefit for patients with sympathetically-maintained pain in CRPS, although the reference for this statement is ignored
  • The procedure can result in pain relief through disruption of sympathetic pain pathways, improved quality of life, potential reduction in central sensitization, and facilitation of participation in physical therapy and rehabilitation, as stated by the American Society of Regional Anesthesia and Pain Medicine, although no specific citation is provided

Adjunctive Therapies

  • Topical agents (menthol cream, capsaicin patches) can be considered as adjunctive therapies for pain management, as recommended by the American Society of Clinical Oncology 1
  • Physical therapy can improve function, and psychological support can be provided for pain management, as stated by the American Physical Therapy Association and the American Psychological Association, although no specific citations are provided

Guidelines and Recommendations

  • The MCG and Aetna CPB guidelines state that patients with documented chronic neuropathic pain related to chemotherapy, who have failed maximum medical therapy with first-line agents, and have symptoms consistent with CRPS type one, meet the criteria for a right lumbar sympathetic nerve block, as recommended by the Milliman Care Guidelines and the Aetna Clinical Policy Bulletin, although no specific citation is provided
  • The American College of Cardiology is not relevant to this topic, and the American Society of Clinical Oncology provides relevant recommendations 1